Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A 2

Journal of Medicinal Chemistry

Volumn 50, Issue 17, 2007, Pages 4222-4235

  Six, David A ^a   Barbayianni, Efrosini ^b   Loukas, Vassilios ^b   Constantinou Kokotou, Violetta ^c   Hadjipavlou Litina, Dimitra ^d   Stephens, Daren ^a   Wong, Alan C ^a   Magrioti, Victoria ^b   Moutevelis Minakakis, Panagiota ^b   Baker, Sharon F ^a   Dennis, Edward A ^a   Kokotos, George ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 OXOHEXADECANAMIDO)OCTANOIC ACID; 5 (2 OXOHEXADECANAMIDO)NONANOIC ACID; AMIDE; AMINO ACID DERIVATIVE; GROUP IVA CYTOSOLIC PHOSPHOLIPASE A2; GROUP V SECRETED PHOSPHOLIPASE A2; GROUP VIA CALCIUM INDEPENDENT PHOSPHOLIPASE A2; ICOSANOID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME INHIBITION; ENZYME RELEASE; INFLAMMATION; NONHUMAN; PAIN; RAT; STRUCTURE ACTIVITY RELATION;

AMIDES; AMINO ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; EDEMA; HUMANS; INFLAMMATION; PAIN; PHOSPHOLIPASES A; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548125295     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0613673     Document Type: Article

References (80)

1. Six, D. A.; Dennis, E. A. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim. Biophys. Acta 2000, 1488, 1-19.
2. Leslie, C. C. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. Prostaglandins, Leukotrienes, Essent. Fatty Acids 2004, 70, 373-376.
3. Schaloske, R. H.; Dennis, E. A. The phospholipase A(2) superfamily and its group numbering system. Biochim. Biophys. Acta 2006, 1761, 1246-1259.
4. 2. Probing the role of histidine, aspartic acid, cysteine, and arginine. J. Biol. Chem. 1996, 271, 19225-19231.
5. Dessen, A.; Tang, J.; Schmidt, H.; Stahl, M.; Clark, J. D.; Seehra, J.; Somers, W. S. Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. Cell 1999, 97, 349-360.
6. Bonventre, J. V.; Huang, Z.; Taheri, M. R.; O'Leary, E.; Li, E.; Moskowitz, M. A.; Sapirstein, A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 1997, 390, 622-625.
7. Uozumi, N.; Kume, K.; Nagase, T.; Nakatani, N.; Ishii, S.; Tashiro, F.; Komagata, Y.; Maki, K.; Ikuta, K.; Ouchi, Y.; Miyazaki, J.; Shimizu, T. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 1997, 390, 618-622.
8. Rubin, B. B.; Downey, G. P.; Koh, A.; Degousee, N.; Ghomashchi, F.; Nallan, L.; Stefanski, E.; Harkin, D. W.; Sun, C.; Smart, B. P.; Lindsay, T. F.; Cherepanov, V.; Vachon, E.; Kelvin, D.; Sadileki M.; Brown, G. E.; Yaffe, M. B.; Plumb, J.; Grinstein, S.; Glogauer, M.; Gelb, M. H. Cytosolic phospholipase A2-alpha is necessary for platelet-activating factor biosynthesis, efficient neutrophil-mediated bacterial killing, and the innate immune response to pulmonary infection: cPLA2-alpha does not regulate neutrophil NADPH oxidase activity. J. Biol. Chem. 2005, 280, 7519-7529.
9. Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294, 1871-1875.
10. Yaksh, T. L.; Kokotos, G.; Svensson, C. I.; Stephens, D.; Kokotos, C. G.; Fitzsimmons, B.; Hadjipavlou-Litina, D.; Hua, X. Y.; Dennis, E. A. Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin E2 release. J. Pharmacol. Exp. Ther. 2006, 316, 466-475.
11. Meyer, M. C.; Rastogi, P.; Beckett, C. S.; McHowat, J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr. Pharm. Des. 2005, 11, 1301-1312.
12. Yedgar, S.; Cohen, Y.; Shoseyov, D. Control of phospholipase A(2) activities for the treatment of inflammatory conditions. Biochim. Biophys. Acta 2006, 1761, 1373-1382.
13. Uozumi, N.; Shimizu, T. Roles for cytosolic phospholipase A2alpha as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediators 2002, 68-69, 59-69.
14. Ghosh, M.; Tucker, D. E.; Burchett, S. A.; Leslie, C. C. Properties of the group IV phospholipase A(2) family. Prog. Lipid Res. 2006, 45, 487-510.
15. Ghomashchi, F.; Stewart, A.; Hefner, Y.; Ramanadham, S.; Turk, J.; Leslie, C. C.; Gelb, M. H. A pyrrolidine-based specific inhibitor of cytosolic phospholipase A(2)alpha blocks arachidonic acid release in a variety of mammalian cells. Biochim. Biophys. Acta 2001, 1513, 160-166.
16. Bellido-Reyes, Y. A.; Akamatsu, H.; Kojima, K.; Arai, H.; Tanaka, H.; Sunamori, M. Cytosolic phospholipase A2 inhibition attenuates ischemia-reperfusion injury in an isolated rat lung model. Transplantation 2006, 81, 1700-1707.
17. Malaviya, R.; Ansell, J.; Hall, L.; Fahmy, M.; Argentieri, R. L.; Olini, G. C., Jr.; Pereira, D. W.; Sur, R.; Cavender, D. Targeting cytosolic phospholipase A2 by arachidonyl trifluoromethyl ketone prevents chronic inflammation in mice. Eur. J. Pharmacol. 2006, 539, 195-204.
18. Phillips, R. M.; Six, D. A.; Dennis, E. A.; Ghosh, P. In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors. J. Biol. Chem. 2003, 278, 41326-41332.
19. Stephens, D.; Barbayianni, E.; Constantinou-Kokotou, V.; Peristeraki, A.; Six, D. A.; Cooper, J.; Harkewicz, R.; Deems, R. A.; Dennis, E. A.; Kokotos, G. Differential inhibition of group IVA and group VIA phospholipases A(2) by 2-oxoamides. J. Med. Chem. 2006, 49, 2821-2828.
20. Winstead, M. V.; Balsinde, J.; Dennis, E. A. Calcium-independent phospholipase A(2): structure and function. Biochim. Biophys. Acta 2000, 1488, 28-39.
21. Balsinde, J.; Balboa, M. A. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A(2) in activated cells. Cell. Signalling 2005, 17, 1052-1062.
22. Masuda, S.; Murakami, M.; Ishikawa, Y.; Ishii, T.; Kudo, I. Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues. Biochim. Biophys. Acta 2005, 1736, 200-210.
23. Wijewickrama, G. T.; Kim, J. H.; Kim, Y. J.; Abraham, A.; Oh, Y.; Ananthanarayanan, B.; Kwatia, M.; Ackerman, S. J.; Cho, W. Systematic evaluation of transcellular activities of secretory phospholipases A2. High activity of group V phospholipases A2 to induce eicosanoid biosynthesis in neighboring inflammatory cells. J. Biol. Chem. 2006, 281, 10935-10944.
24. Singer, A. G.; Ghomashchi, F.; Le Calvez, C.; Bollinger, J.; Bezzine, S.; Rouault, M.; Sadilek, M.; Nguyen, E.; Lazdunski, M.; Lambeau, G.; Gelb, M. H. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J. Biol. Chem. 2002, 277, 48535-48549.
25. Winget, J. M.; Pan, Y. H.; Bahnson, B. J. The interfacial binding surface of phospholipase A2s. Biochim. Biophys. Acta 2006, 1761, 1260-1269.
26. Cho, W. Structure, function, and regulation of group V phospholipase A(2). Biochim. Biophys. Acta 2000, 1488, 48-58.
27. Satake, Y.; Diaz, B. L.; Balestrieri, B.; Lam, B. K.; Kanaoka, Y.; Grusby, M. J.; Arm, J. P. Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J. Biol. Chem. 2004, 279, 16488-16494.
28. 2+-independent group VI phospholipase A2s in P388D1 macrophages using GFP/RFP constructs. Biochim. Biophys. Acta 2005, 1735, 119-129.
29. Kokotos, G.; Kotsovolou, S.; Six, D. A.; Constantinou-Kokotou, V.; Beltzner, C. C.; Dennis, E. A. Novel 2-oxoamide inhibitors of human group IVA phospholipase A(2). J. Med. Chem. 2002, 45, 2891-2893.
30. Kokotos, G.; Six, D. A.; Loukas, V.; Smith, T.; Constantinou-Kokotou, V.; Hadjipavlou-Litina, D.; Kotsovolou, S.; Chiou, A.; Beltzner, C. C.; Dennis, E. A. Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivo. J. Med. Chem. 2004, 47, 3615-3628.
31. Constantinou-Kokotou, V.; Peristeraki, A.; Kokotos, C. G.; Six, D. A.; Dennis, E. A. Synthesis and activity of 2-oxoamides containing long chain beta-amino acids. J. Pept. Sci. 2005, 11, 431-435.
32. 2. In Peptides 2004, Proceedings of the 3rd International and 28th European Peptide Symposium, Prague, Czech Republic, September 5-10, 2004; Flegel, M., Fridkin, M., Gilon, C. Slaninova, J., Eds.; KENES International: Geneva, Switzerland, 2005; pp 615-616.
33. 2 and Present in Vivo Anti-Inflammatory Activity. In Peptides 2004, Proceedings of the 3rd International and 28th European Peptide Symposium, Prague, Czech Republic, September 5-10, 2004; Flegel, M., Fridkin, M., Gilon, C., Slaninova, J., Eds.; KENES International: Geneva, Switzerland, 2005; pp 643-644.
34. 2. In 4th Hellenic Forum on Bioactive Peptides; Cordopatis, P. A., Manessi-Zoupa, E., Pairas, G., Eds.; TYPORAMA: Patras, Greece, 2005; pp 247-251.
35. Kokotos, G.; Constantinou-Kokotou, V.; Noula, C.; Nicolaou, A.; Gibbons, W. A. Synthesis of lipidic amino acid and dipeptide inhibitors of human platelet phospholipase A2. Int. J. Pept. Protein Res. 1996, 48, 160-166.
36. Leanna, M. R.; Sowin, T. J.; Morton, H. E. Synthesis of alpha-amino and alpha-alkoxy aldehydes via oxoammonium oxidation. Tetrahedron Lett. 1992, 33, 5029-5032.
37. Ma, Z.; Bobbitt, J. M. Organic oxoammonium salts: a new convenient method for the oxidation of alcohols to aldehydes and ketones. J. Org. Chem. 1991, 56, 6110-6114.
38. Takacs, J. M.; Jaber, M. R.; Clement, F.; Walters, C. A useful ' procedure for the preparation of (E,E)-2,4-dienoates: lithium hydroxide-promoted dienylation by 4-phosphonocrotonate. J. Org. Chem. 1998, 63, 6757-6760.
39. Kokotos, G.; Noula, C. Selective one-pot conversion of carboxylic acids into alcohols. J. Org. Chem. 1996, 61, 6994-6996.
40. Kokotos, G. A convenient one-pot conversion of N-protected amino-acids and peptides into alcohols. Synthesis 1990, 299-301.
41. Nunez, M. T.; Martin, V. S. Efficient oxidation of phenyl groups to carboxylic-acids with ruthenium tetraoxide - a simple synthesis of (R)-gamma-caprolactone, the pheromone of trogoderma-granarium. J. Org. Chem. 1990, 55, 1928-1932.
42. Moutevelis-Minakakis, P.; Sinanoglou, C.; Loukas, V.; Kokotos, G. Synthesis of non-natural amino acids based on the ruthenium-catalysed oxidation of a phenyl group to carboxylic acid. Synthesis 2005, 933-938.
43. Clark, J. D.; Lin, L. L.; Kriz, R. W.; Ramesha, C. S.; Sultzman, L. A.; Lin, A. Y.; Milona, N.; Knopf, J. L. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell 1991, 65, 1043-1051.
44. Street, I. P.; Lin, H. K.; Laliberte, F.; Ghomashchi, F.; Wang, Z.; Perrier, H.; Tremblay, N. M.; Huang, Z.; Weech, P. K.; Gelb, M. H. Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2. Biochemistry 1993, 32, 5935-5940.
45. 2: structure-function studies with vesicle, micelle, and membrane assays. Biochim. Biophys. Acta 1999, 1420, 45-56.
46. Leslie, C. C. Kinetic properties of a high molecular mass arachidonoyl-hydrolyzing phospholipase A2 that exhibits lysophospholipase activity. J. Biol. Chem. 1991, 266, 11366-11371.
47. 2. Biochim. Biophys. Acta 1993, 1167, 272-280.
48. 2. J. Biol. Chem. 1997, 272, 19214-19219.
49. 2. J. Am. Chem. Soc. 1996, 118, 5519-5525.
50. Magrioti, V.; Kokotos, G. Synthetic inhibitors of group IVA and group VIA phospholipase A2. Anti-Inflammatory Anti-Allergy Agents Med. Chem. 2006, 5, 189-203.
51. McKew, J. C.; Foley, M. A.; Thakker, P.; Behnke, M. L.; Lovering, F. E.; Sum, F. W.; Tam, S.; Wu, K.; Shen, M. W.; Zhang, W.; Gonzalez, M.; Liu, S.; Mahadevan, A.; Sard, H.; Khor, S. P.; Clark, J. D. Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization. J. Med. Chem. 2006, 49, 135-158.
52. Kokotos, G.; Verger, R.; Chiou, A. Synthesis of 2-oxo amide triacylglycerol analogues and study of their inhibition effect on pancreatic and gastric lipases. Chem.-Eur. J. 2000, 6, 4211-4217.
53. Kotsovolou, S.; Chiou, A.; Verger, R.; Kokotos, G. Bis-2-oxo amide triacylglycerol analogues: a novel class of potent human gastric lipase inhibitors. J. Org. Chem. 2001, 66, 962-967.
54. Gelb, M. H.; Svaren, J. P.; Abeles, R. H. Fluoro ketone inhibitors of hydrolytic enzymes. Biochemistry 1985, 24, 1813-1817.
55. White, S. P.; Scott, D. L.; Otwinowski, Z.; Gelb, M. H.; Sigler, P. B. Crystal structure of cobra-venom phospholipase A2 in a complex with a transition-state analogue. Science 1990, 250, 1560-1563.
56. Reid, R. C. Inhibitors of secretory phospholipase A2 group IIA. Curr. Med. Chem. 2005, 12, 3011-3026.
57. Smart, B. P.; Pan, Y. H.; Weeks, A. K.; Bollinger, J. G.; Bahnson, B. J.; Gelb, M. H. Inhibition of the complete set of mammalian secreted phospholipases A(2) by indole analogues: a structure-guided study. Bioorg. Med. Chem. 2004, 12, 1737-1749.
58. Zeiher, B. G.; Steingrub, J.; Laterre, P. F.; Dmitrienko, A.; Fukiishi, Y.; Abraham, E. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit. Care Med. 2005, 33, 1741-1748.
59. Bowton, D. L.; Dmitrienko, A. A.; Israel, E.; Zeiher, B. G.; Sides, G. D. Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma. J. Asthma 2005, 42, 65-71.
60. Bradley, J. D.; Dmitrienko, A. A.; Kivitz, A. J.; Gluck, O. S.; Weaver, A. L.; Wiesenhutter, C.; Myers, S. L.; Sides, G. D. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J. Rheumatol. 2005, 32, 417-423.
61. OmPraba, G.; Velmurugan, D. Quantitative structure-activity relationship (QSAR) analysis of a series of indole analogues as inhibitor for human group V secretory phospholipase A2. Indian J. Biochem. Biophys. 2006, 43, 154-159.
62. Smart, B. P.; Pan, Y. H.; Weeks, A. K.; Bollinger, J. G.; Bahnson, B. J.; Gelb, M. H. Inhibition of the complete set of mammalian secreted phospholipases A(2) by indole analogues: a structure-guided study. Bioorg. Med. Chem. 2004, 12, 1737-1749.
63. Smart, B. P.; Oslund, R. C.; Walsh, L. A.; Gelb, M. H. The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. J. Med. Chem. 2006, 49, 2858-2860.
64. 2 with phospholipid analogues and inhibitors. J. Biol. Chem. 1990, 265, 2657-2664.
65. 2 using amide substrate analogues. J. Am. Chem. Soc. 1992, 114, 8757-8763.
66. Sapirstein, A.; Bonventre, J. V. Specific physiological roles of cytosolic phospholipase A(2) as defined by gene knockouts. Biochim. Biophys. Acta 2000, 1488, 139-148.
67. Serhan, C. N. Preventing injury from within, using selective cPLA2 inhibitors. Nat. Immunol. 2000, 1, 13-15.
68. Cicero, A. F.; Derosa, G.; Gaddi, A. Combined lipoxygenase/cyclooxygenase inhibition in the elderly: the example of licofelone. Drugs Aging 2005, 22, 393-403.
69. Martel-Pelletier, J.; Lajeunesse, D.; Reboul, P.; Pelletier, J. P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2003, 62, 501-509.
70. Mitchell, J. A.; Warner, T. D. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat. Rev. Drug Discovery 2006, 5, 75-86.
71. Moreau, M.; Daminet, S.; Martel-Pelletier, J.; Fernandes, J.; Pelletier, J. P. Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. J. Vet. Pharmacol. Ther. 2005, 28, 81-86.
72. 2. Biochim. Biophys. Acta 1998, 1394, 57-64.
73. Othman, R.; Baker, S.; Li, Y.; Worrall, A. F.; Wilton, D. C. Human non-pancreatic (group II) secreted phospholipase A2 expressed from a synthetic gene in Escherichia coli: characterisation of N-terminal mutants. Biochim. Biophys. Acta 1996, 1303, 92-102.
74. Baker, S. F.; Othman, R.; Wilton, D. C. Tryptophan-containing mutant of human (group IIa) secreted phospholipase A2 has a dramatically increased ability to hydrolyze phosphatidylcholine vesicles and cell membranes. Biochemistry 1998, 37, 13203-13211.
75. 2. Anal. Biochem. 1999, 269, 278-288.
76. Reynolds, L. J.; Washburn, W. N.; Deems, R. A.; Dennis, E. A. Assay Strategies and Methods for Phospholipases. In Methods in Enzymology; Dennis, E. A., Ed.; Academic Press: Orlando, FL, 1991; Vol. 197, pp 3-23.
77. Ono, T.; Yamada, K.; Chikazawa, Y.; Ueno, M.; Nakamoto, S.; Okuno, T.; Seno, K. Characterization of a novel inhibitor of cytosolic phospholipase A2alpha, pyrrophenone. Biochem. J. 2002, 363, 727-735.
78. Seno, K.; Okuno, T.; Nishi, K.; Murakami, Y.; Yamada, K.; Nakamoto, S.; Ono, T. Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative "pyrrophenone". Bioorg. Med. Chem. Lett. 2001, 11, 587-590.
79. Kontogiorgis, C.; Hadjipavlou-Litina, D. Biological evaluation of several coumarin derivatives designed as possible anti-inflammatory/ antioxidant agents. J. Enzyme Inhib. Med. Chem. 2003, 18, 63-69.
80. Hadjipavlou-Litina, D.; Rekka, E.; Hadjipetrou-Kourounakis, L.; Kourounakis, P. Synthesis and biological studies of some novel antiinflammatory aryl-hydroxy-amino-ketones. Eur. J. Med. Chem. 1991, 26, 85-90.